Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 3/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.37 |
| ▸ | MVD | P53602 | 2/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3002864 | 1.00 | BTN3A1 (0.45) | BTN3A1LPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL3004975 | 1.00 | BTN3A1 (0.45) | BTN3A1LPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL3004918 | 1.00 | BTN3A1 (0.45) | BTN3A1LPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL2999226 | 1.00 | BTN3A1 (0.45) | BTN3A1LPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL3004732 | 1.00 | BTN3A1 (0.45) | BTN3A1LPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL3005196 | 1.00 | BTN3A1 (0.45) | BTN3A1LPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL2993317 | 1.00 | BTN3A1 (0.45) | BTN3A1LPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL2995236 | 1.00 | BTN3A1 (0.45) | BTN3A1LPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL2995155 | 1.00 | BTN3A1 (0.45) | BTN3A1LPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL3005228 | 1.00 | BTN3A1 (0.45) | BTN3A1LPAR3LPAR2LPAR1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | INNATE PHARMA, S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-20100189681-A1 | Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer | INNATE PHARMA S.A. (FR) | 2010-07-29 | — | — | US | disclosed |
| WO-2010049438-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS FOR THE TREATMENT OF DISEASES | INNATE PHARMA (FR) | 2010-05-06 | — | — | WO | disclosed |
| EP-1569656-B1 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | INNATE PHARMA (FR) | 2010-03-03 | — | — | EP | disclosed |
| EP-2150258-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS TOGETHER WITH INTERLEUKIN-2 FOR THE TREATMENT OF CANCER | Innate Pharma S.A. (FR) | 2010-02-10 | — | — | EP | disclosed |
| US-20100029674-A1 | Methods of Using Phosphoantigen for the Treatment of Cancer | INNATE PHARMA, S.A. (FR) | 2010-02-04 | — | — | US | disclosed |
| US-20090304688-A1 | Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using Gamma Delta T Cell Activators | INNATE PHARMA S.A. (FR) | 2009-12-10 | — | — | US | disclosed |
| EP-2083830-A1 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | Innate Pharma (FR) | 2009-08-05 | — | — | EP | disclosed |
| EP-2040750-A2 | METHODS AND COMPOSITIONS FOR INCREASING THE EFFICIENCY OF THERAPEUTIC ANTIBODIES USING GAMMA DELTA T CELL ACTIVATORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008059052-A9 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | INNATE PHARMA (FR) | 2009-03-12 | — | — | WO | disclosed |
| WO-2007057440-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | INNATE PHARMA (FR) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007039635-A2 | PHOSPHOANTIGEN SALTS OF ORGANIC BASES AND METHODS FOR THEIR CRYSTALLIZATION | INNATE PHARMA (FR) | 2007-04-12 | — | — | WO | disclosed |
| US-20060287274-A1 | Phosphoepoxides, method for making same and uses | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2006-12-21 | — | — | US | disclosed |
| EP-1720567-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA | Innate Pharma (FR) | 2006-11-15 | — | — | EP | disclosed |
| US-7101711-B1 | Phosphoepoxides, method for making same and uses | INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE (FR) | 2006-09-05 | — | — | US | disclosed |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | INNATE PHARMA, S.A.S. (FR) | 2006-08-31 | — | — | US | disclosed |
| WO-2005077411-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA | INNATE PHARMA (FR) | 2005-08-25 | — | — | WO | disclosed |
| EP-1109818-B1 | PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES | INST NAT SANTE RECH MED (FR) | 2002-11-06 | — | — | EP | disclosed |
| EP-1109818-A1 | PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012519-A1 | PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | IFNG, IL2, ICOS | BTN3A1 288/4885LPAR3 1385/4885LPAR2 1444/4885 |
| US-20060287274-A1 | Phosphoepoxides, method for making same and uses | CD4, CCR9, BCL9 | BTN3A1 315/4885LPAR3 868/4885LPAR2 749/4885 |
| US-20100029674-A1 | Methods of Using Phosphoantigen for the Treatment of Cancer | CD4, CD74, TP53 | BTN3A1 536/4885LPAR3 1706/4885LPAR2 1894/4885 |
| US-20100189681-A1 | Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer | IL2, IL2RA, CD4 | BTN3A1 539/4885LPAR3 1798/4885LPAR2 580/4885 |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | IFNG, IL2, ICOS | BTN3A1 279/4885LPAR3 1486/4885LPAR2 1736/4885 |
| US-20090304688-A1 | Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using Gamma Delta T Cell Activators | CD4, FCGR3B, IFNG | BTN3A1 135/4885LPAR3 830/4885LPAR2 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.